The biotech's partner completed enrollment in a key clinical study.
Compare ATHX Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: Athersys
The biotech announced the enrollment of the first patient in a key clinical study.
The stem cell stock jumped after a major Wall Street firm initiated coverage, but there's a catch.
The stem cell stock recovered from a lousy April as the company fed investors updates for its COVID-19 programs.
The stem cell stock has delivered a 100% gain since the beginning of the year. Can it hold?
Promising results from a very small study caused shares of stem cell stocks to soar, but investors shouldn't get too carried away just yet.
The stem cell developer decided to wisely take advantage of a soaring share price to raise funds.
The FDA has given the company's lead drug platform a potential leg up in development.
The stem cell pioneer announced an update with its most important collaborator.
An investment bank analyst predicts off-the-hook gains from Athersys' "off-the-shelf" stem cell treatments.